RAPPORT THERAPEUTICS INC

Explore Rapport Therapeutics’ CEO insider sale—structured, rule‑based, and steady—while the firm hits a 52‑week high and a $2.4B market cap, offering investors a clear view of growth prospects and risk factors.

Insightful report on Rapport Therapeutics’ insider sales and CNS drug pipeline, highlighting FDA fast‑track prospects for RT‑CNS‑01.

Insider sales by Rapport Therapeutics’ CEO show disciplined rebalancing, but option purchases signal confidence in the company’s pipeline and future growth prospects.

Insider buying of 120k options signals confidence in the company’s CNS drug RAP‑219; read how leadership’s stake and early payer deals could shape future value.

Rapport Therapeutics’ insider buying shows confidence in RAP‑219, a CNS‑targeted pain drug, as Phase IIb trials aim for FDA‑approved relief with minimal side effects.

Insider sale of 8,500 RAPP shares by CSO Bredt David shows disciplined liquidity management, not panic—watch Phase 3 results for potential upside.